This is the second of a two-part report on the pharmaceutical industry. Part II begins with a discussion of foreign direct investment and inter-firm networks, which covers international mergers, acquisitions, and minority participation; market shares of foreign-controlled firms; international collaboration agreements (with a special note on agreements in biotechnology); and licensing agreements. The final section of the report covers governmental policies on health and safety regulation, price regulation, industry and technology, trade, foreign investment, protection of intellectual property, and competition.
Get full access to this article
View all access options for this article.
References
1.
De WolfP. In L'Europe et la globalisation: Acquisitions et accords dans l'industrie, edited by SachwaldF.. Masson, Paris, 1993.
2.
BallanceR.PoganyJ., and ForstnerH.The World's Pharmaceutical Industries. UNIDO, Edward Elgar, Aldershot, 1992.
3.
JaffeJ.Collaboration Agreements in Pharmaceuticals. Report prepared under the direction of D. Morris, INSEAD.
VickeryG.A survey of international technology licensing. STI Rev.4. OECD, Paris, 1988.
6.
FCCSET Committee.Biotechnology for the 21st Century. 1992.
7.
Commission of the European Communities.XXth Report on Competition Policy. Brussels.
8.
Commission of the European Communities.Panorama of EU Industry 94. Brussels, 1994.
9.
TarabusiCasadio C.Globalisation in the pharmaceutical industry: Technological change and competition in a triad perspective. STI Rev.13. OECD, Paris, 1993.
10.
Chemical industry R&D spending to rise modestly.Chem. Eng. News, January 25, 1993.
11.
Commission of the European Communities.Panorama of EC Industries 1991–92. Brussels, 1993.
12.
Commission of the European Communities.Panorama of EC Industries 93. Brussels, 1994.
13.
DaltonD. H., and SerapioM. G.U.S. Research Facilities of Foreign Companies. U.S. Department of Commerce, 1992.
14.
EAG.Generic Pharmaceuticals: The Threat. London, 1989.
15.
Financial Times, May 9, 1994 [quoting Ernst and Young].
16.
GrubelH. G., and LloydP. J.Intra-industry Trade: The Theory and Measurement of International Trade in Differentiated Products. Macmillan, London, 1975.
17.
Japanese chemical companies still mired in slump.Chem. Eng. News, February 8, 1993.
18.
OECD.Competition Policy in OECD Countries. Paris, various issues.
19.
OECD.Globalisation of Industrial Activities: Four Case Studies. Paris, 1992.
20.
OECD.Health Care Data File. Paris, 1994.
21.
OECD.The International Sourcing of Manufactured Intermediate Inputs: By Canada, France, Germany, Japan, the United Kingdom and the United States. Paris, 1992.
22.
OECD.Intra-firm Trade. Paris, 1993.
23.
OECD.The Pharmaceutical Industry: Trade Related Issues. Paris, 1985.
24.
RaugelP.-J.European biotechnology investments in North America and Japan. BFE 9, November/December 1992.
25.
SchreyerP.Competition policy and industrial adjustment. STI Rev.10. OECD, Paris, 1992.
26.
SCRIP.Pharmaceutical Company League Tables. PJB Publications, Surrey, England, 1981, 1982, 1990, 1991, 1992, 1993 [and other SCRIP publications].
27.
U.S. Congress, Office of Technology Assessment. Multinationals and the U.S. Technology Base. U.S. Government Printing Office, Washington, D.C., 1994.
28.
U.S. Department of Commerce.Foreign Direct Investment in the United States. Washington, D.C., 1991.
29.
U.S. Department of Commerce.Foreign Direct Investment in the United States: An Update. Washington, D.C., 1993.
30.
U.S. Department of Commerce.U.S. Industrial Outlook 1992, 1993 and 1994. Washington, D.C., various years.
31.
U.S. International Trade Commission.Global Competitiveness of U.S. Advanced-Technology Manufacturing Industries: Pharmaceuticals. U.S.ITC Publication 2437. Washington, D.C., September 1991.
